Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients.
van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH. van Andel L, et al. Among authors: kansra v. Cancer Chemother Pharmacol. 2018 Jan;81(1):39-46. doi: 10.1007/s00280-017-3455-x. Epub 2017 Oct 17. Cancer Chemother Pharmacol. 2018. PMID: 29043410 Free PMC article. Clinical Trial.
Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine.
van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Rosing H, Schellens JHM, Beijnen JH. van Andel L, et al. Among authors: kansra v. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 1;1040:14-21. doi: 10.1016/j.jchromb.2016.11.020. Epub 2016 Nov 19. J Chromatogr B Analyt Technol Biomed Life Sci. 2017. PMID: 27898364
Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer.
van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Lucas L, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH. van Andel L, et al. Among authors: kansra v. Invest New Drugs. 2017 Dec;35(6):751-765. doi: 10.1007/s10637-017-0451-2. Epub 2017 Mar 16. Invest New Drugs. 2017. PMID: 28303528 Free PMC article.
Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.
Wang X, Zhang ZY, Arora S, Hughes L, Wang J, Powers D, Christensen J, Lu S, Kansra V. Wang X, et al. Among authors: kansra v. J Clin Pharmacol. 2018 Feb;58(2):202-211. doi: 10.1002/jcph.1005. Epub 2017 Sep 14. J Clin Pharmacol. 2018. PMID: 28906558 Clinical Trial.
37 results